What is OBI Pharma’s OBI-992 and which clinical trial is registered in the United States?
OBI Pharma’s OBI-992 is a TROP2-targeting ADC linking an antibody to exatecan through a cleavable peptide linker. [1]
ClinicalTrials.gov lists NCT06480240 as a Phase 1/2 study in advanced solid tumors with U.S. sites; its status is ACTIVE_NOT_RECRUITING and its last posted update is August 8, 2025. [1]
Dated evidence
| Claim | Value | As of | Source and original quotation |
|---|---|---|---|
| ADC composition | TROP2-targeting antibody, cleavable peptide linker and exatecan | 2025-08-08 | Primary sourceAnti-TROP2 antibody drug conjugate |
| Registered trial | NCT06480240; Phase 1/2; advanced solid tumors | 2025-08-08 | Primary sourceNCT06480240 |
| Registry status | ACTIVE_NOT_RECRUITING | 2025-08-08 | Primary sourceACTIVE_NOT_RECRUITING |
| Last posted update | 2025-08-08 | 2025-08-08 | Primary source2025-08-08 |
| US study locations | United States study sites | 2025-08-08 | Primary sourceUnited States |
Not disclosed in the public documents
The public registry record retrieved for this card does not contain posted study results or a confirmed marketing-approval date. Document reviewed 2026-10-22
NCT06480240